Immunovaccine
About Us
Overview
Leadership
Board of Directors
Scientific and Clinical Advisory Committee
Company History
Business Development
Partnerships
Careers
Overview
Openings
Life at IMV
Clinical Trials
Overview
Ongoing Trials
DPX-Survivac
Platform
Overview
Other Applications
Intellectual Property
Publications
Research and Development
Overview
Immuno-oncology
Investors
Overview
Press Releases
Events, Webcasts & Presentations
Financial Info
Stock Data
Filings
Governance
Contact Us
FAQ
Newsroom
Latest News
Archives
Media Contact
Contact Us
Clinical Trials
- Overview
- Ongoing Trials
-- Expanded Access
-- Investigator-initiated Trials
- DPX-Survivac
Research and Development
- Overview
- Immuno-oncology
-- Ovarian Cancer
Platform
- Overview
- Other Applications
-- Infectious Diseases
- Intellectual Property
- Publications
About Us
- Overview
- Leadership
- Board of Directors
- SCAC
- Company History
- Business Development
- Partnerships
Investors
- Stock Information
- Press Releases
- Analyst Coverage
- Events, Webcasts, Presentations
- Financial Information
- Tax Information
- Proxy Information
- SEC Filings
- SEDAR Regulatory Filings
- Corp Governance
- Investor FAQs
- Contact Us
Newsroom
- Overview
- Archives
- Media Contact
Contact Us
Careers
- Overview
- Openings
- Life at Immunovaccine
- Life in Halifax
Financial Information
Investors
Investors
Overview
Press Releases
Events, Webcasts & Presentations
Overview
Presentations
Scientific Posters
Email Alerts
Financial Info
Financial Results
Tax Info
Proxy Info
Stock Option Plan
Deferred Share Unit Plan
Stock Data
NASDAQ: IMV
TSX: IMV
Analyst Coverage
Filings
All SEC Filings
Annual Reports
SEDAR
Governance
Overview
Board of Directors
Board Committees
Governance Documents
Contact Us
FAQ
Financial Info
Financial Results
Tax Info
Proxy Info
Stock Option Plan
Deferred Share Unit Plan
Latest Financial Results
Q1 2020
Quarter Ended Mar 31, 2020
Earnings Release
PDF
HTML
Audio
Earnings Webcast
MD&A
PDF
Financial Reports
PDF
Email Alerts
Contacts
RSS News Feed